Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study

Overview

Journal Psoriasis (Auckl)

Publisher Dove Medical Press

Date 2022 Jul 21

PMID 35859710

Authors

Matteo Megna

Luca Potestio

Gabriella Fabbrocini

Angelo Ruggiero

Affiliations

Soon will be listed here.

Abstract

Introduction: Guselkumab safety and efficacy profiles in psoriasis have been showed by VOYAGE (1 and 2) trials. Although trial results have been already previously confirmed by real-life studies, long-term real-life data, and drug survival data about guselkumab are still poor.

Patients And Methods: We performed a 3-year retrospective study, with the aim of assessing guselkumab efficacy and safety profile in the management of plaque psoriasis in a real-life setting.

Results: Thirty-one patients completed the study. Both Psoriasis Area Severity Index (PASI) and Body Surface Area (BSA) statistically improved since week 16, and up to week 144 [PASI reduction from 16.4 ± 6.2 to 0.6 ± 0.9 (p < 0.0001) at week 144 while BSA from 33.2 ± 14.6 to 1.9 ± 1.4 (p < 0.0001)]. At week 12 PASI90 and PASI100 were achieved by 19 (61.3%) and 11 (35.4%) patients, respectively, as well as 24 (77.4%) and 18 (58.1%) subjects reached PASI 90 and PASI 100 at week 144. As regards the safety, no cases of injection site reaction, candida, serious AEs, malignancy, or major cardiovascular events were reported. Of note, mild AEs were collected with pharyngitis as the main one (7, 22.6%), followed by headache (5, 16.1%) and flu-like illness (5, 16.1%), all without requiring treatment discontinuation.

Conclusion: Our experience confirmed the efficacy and safety of guselkumab in daily clinical practice up to 3 years, suggesting this drug as an effective treatment option in psoriasis long-term management.

Citing Articles

Characterization of Super-Responder Profile in Chronic Plaque Psoriatic Patients under Guselkumab Treatment: A Long-Term Real-Life Experience.

Marcelli L, Belcastro A, Talamonti M, Paganini C, Fico A, Savastano L J Clin Med. 2024; 13(17).

PMID: 39274388 PMC: 11396162. DOI: 10.3390/jcm13175175.

Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial.

Puig L, Costanzo A, de Jong E, Torres T, Warren R, Wapenaar R Am J Clin Dermatol. 2023; 25(2):315-325.

PMID: 37804472 PMC: 10866772. DOI: 10.1007/s40257-023-00816-1.

Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2.

Kim B, Jo S, Youn S, Reich K, Saadoun C, Chang C Dermatol Ther (Heidelb). 2023; 13(11):2721-2737.

PMID: 37750995 PMC: 10613179. DOI: 10.1007/s13555-023-01026-7.

Biologics for the Management of Erythrodermic Psoriasis: An Updated Review.

Potestio L, Camela E, Cacciapuoti S, Fornaro L, Ruggiero A, Martora F Clin Cosmet Investig Dermatol. 2023; 16:2045-2059.

PMID: 37560255 PMC: 10408653. DOI: 10.2147/CCID.S407813.

Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?.

Megna M, Camela E, Ruggiero A, Battista T, Martora F, Cacciapuoti S Clin Cosmet Investig Dermatol. 2023; 16:1677-1690.

PMID: 37404368 PMC: 10315147. DOI: 10.2147/CCID.S407812.

References

Marasca C, Ruggiero A, Megna M, Annunziata M, Fabbrocini G . Biologics for patients affected by hidradenitis suppurativa in the COVID-19 era: data from a referral center of Southern Italy. J Dermatolog Treat. 2020; 33(1):592. DOI: 10.1080/09546634.2020.1769828. View

Ruggiero A, Potestio L, Camela E, Fabbrocini G, Megna M . Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge. Psoriasis (Auckl). 2022; 12:127-137. PMC: 9189155. DOI: 10.2147/PTT.S367744. View

Blauvelt A, Burge R, Gallo G, Charbonneau B, Malatestinic W, Zhu B . A Retrospective Cohort Analysis of Treatment Patterns Over 1 Year in Patients with Psoriasis Treated with Ixekizumab or Guselkumab. Dermatol Ther (Heidelb). 2022; 12(3):701-714. PMC: 8941031. DOI: 10.1007/s13555-022-00686-1. View

Maliyar K, OToole A, Gooderham M . Long-Term Single Center Experience in Treating Plaque Psoriasis With Guselkumab. J Cutan Med Surg. 2020; 24(6):588-595. DOI: 10.1177/1203475420932514. View

Megna M, Potestio L, Ruggiero A, Camela E, Fabbrocini G . Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study. J Dermatolog Treat. 2022; 33(5):2560-2564. DOI: 10.1080/09546634.2022.2036674. View

Ruggiero A, Fabbrocini G, Cinelli E, Megna M . Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti-interleukin-17 treatment: A real-life 52-week retrospective study. Dermatol Ther. 2020; 34(1):e14673. DOI: 10.1111/dth.14673. View

Ruggiero A, Fabbrocini G, Cinelli E, Megna M . Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study. Dermatol Ther. 2021; 35(1):e15214. PMC: 9285826. DOI: 10.1111/dth.15214. View

Reich K, Armstrong A, Foley P, Song M, Miller M, Shen Y . Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study. Am J Clin Dermatol. 2020; 21(6):881-890. DOI: 10.1007/s40257-020-00555-7. View

Ataseven A, Temiz S, Eren G, Ozer I, Dursun R . Comparison of anti-TNF and IL-inhibitors treatments in patients with psoriasis in terms of response to routine laboratory parameter dynamics. J Dermatolog Treat. 2020; 33(2):1091-1096. DOI: 10.1080/09546634.2020.1801975. View

10.

Megna M, Tommasino N, Potestio L, Battista T, Ruggiero A, Noto M . Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. J Dermatolog Treat. 2022; 33(6):2813-2820. DOI: 10.1080/09546634.2022.2081655. View

11.

Megna M, Potestio L, Gallo L, Caiazzo G, Ruggiero A, Fabbrocini G . Reply to "Psoriasis exacerbation after COVID-19 vaccination: report of 14 cases from a single centre" by Sotiriou E et al. J Eur Acad Dermatol Venereol. 2021; 36(1):e11-e13. PMC: 8656620. DOI: 10.1111/jdv.17665. View

12.

Megna M, Cinelli E, Gallo L, Camela E, Ruggiero A, Fabbrocini G . Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period. Arch Dermatol Res. 2021; 314(6):619-623. DOI: 10.1007/s00403-021-02200-7. View

13.

Megna M, Fabbrocini G, Gallo L, Patri A, Ruggiero A . A Case of Chronic HCV Infection Reactivation in a Psoriasis Patient Treated with Guselkumab. Curr Drug Saf. 2022; 17(4):390-392. DOI: 10.2174/1574886317666220307112926. View

14.

Ruggiero A, Megna M, Fabbrocini G, Martora F . Video and telephone teledermatology consultations during COVID-19 in comparison: patient satisfaction, doubts and concerns. Clin Exp Dermatol. 2022; 47(10):1863-1864. PMC: 9347843. DOI: 10.1111/ced.15286. View

15.

Ruggiero A, Fabbrocini G, Cinelli E, Megna M . Guselkumab and risankizumab for psoriasis: a 44-week indirect real-life comparison. J Am Acad Dermatol. 2021; 85(4):1028-1030. DOI: 10.1016/j.jaad.2021.01.025. View

16.

Iwakura Y, Ishigame H . The IL-23/IL-17 axis in inflammation. J Clin Invest. 2006; 116(5):1218-22. PMC: 1451213. DOI: 10.1172/JCI28508. View

17.

Reich K, Armstrong A, Langley R, Flavin S, Randazzo B, Li S . Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019; 394(10201):831-839. DOI: 10.1016/S0140-6736(19)31773-8. View

18.

Megna M, Ocampo-Garza S, Potestio L, Fontanella G, Gallo L, Cacciapuoti S . New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge?. Biomedicines. 2021; 9(10). PMC: 8533054. DOI: 10.3390/biomedicines9101482. View

19.

Ruiz-Villaverde R, Rodriguez-Fernandez-Freire L, Armario-Hita J, Perez-Gil A, Galan-Gutierrez M . Guselkumab: Mid-term effectiveness, drug survival, and safety in real clinical practice. Dermatol Ther. 2021; 34(2):e14798. DOI: 10.1111/dth.14798. View

20.

Martora F, Marasca C, Fabbrocini G, Ruggiero A . Strategies adopted in a southern Italian referral centre to reduce adalimumab discontinuation: comment on 'Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?'. Clin Exp Dermatol. 2022; 47(10):1864-1865. DOI: 10.1111/ced.15291. View